1256581-66-4

Basic information

• Product Name: Ethyl 2-(4-isopropoxy-3-Methoxyphenyl)acetate
• Synonyms: Ethyl 2-(4-isopropoxy-3-Methoxyphenyl)acetate;Ethyl 4-isopropoxy-3-Methoxyphenylacetate;3-Methoxy-4-(1-methylethoxy)benzeneacetic acid ethyl ester
• CAS NO: 1256581-66-4
• Molecular Formula: C₁₄H₂₀O₄
• Molecular Weight: 252.3062
• Mol File: 1256581-66-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 2-(4-isopropoxy-3-Methoxyphenyl)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-(4-isopropoxy-3-Methoxyphenyl)acetate(1256581-66-4)
• EPA Substance Registry System: Ethyl 2-(4-isopropoxy-3-Methoxyphenyl)acetate(1256581-66-4)

Safety Data

• Hazardous Substances Data: 1256581-66-4(Hazardous Substances Data)

Usage

General Description

Ethyl 2-(4-isopropoxy-3-methoxyphenyl)acetate is a chemical compound with the molecular formula C13H18O4. It is an ester, which means it is formed from the reaction of an alcohol and an acid. This particular ester is derived from ethyl alcohol and 4-isopropoxy-3-methoxyphenylacetic acid. It is commonly used as a flavoring agent in the food and beverage industry due to its pleasant, fruity odor. Additionally, it has potential applications in the pharmaceutical and cosmetic industries. The compound is considered to be a low hazard chemical, with low toxicity and low environmental impact.

Upstream product

• 75-30-9 2-iodo-propane 
• 60563-13-5 ethyl homovanillate 

Downstream Products

• 1313365-54-6 (2-formyl-4-isopropoxy-5-methoxy-phenyl)-acetic acid ethyl ester 
• 1313365-57-9 (S)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1313365-56-8 {2-[(S)-(4-chloro-phenyl)-((S)-2-methyl-propane-2-sulfinylamino)-methyl]-4-isopropoxy-5-methoxy-phenyl}-acetic acid ethyl ester 
• 1313365-55-7 (4-isopropoxy-5-methoxy-2-{[(E)-(S)-2-methyl-propane-2-sulfinylimino]-methyl}-phenyl)-acetic acid ethyl ester 
• 1313363-54-0 (S)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one 
• 1416907-70-4 (S)-1-(4-chloro-phenyl)-2-{4-[1-hydroxy-1-(3-methoxy-phenyl)-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416910-26-3 (S)-1-(4-chloro-phenyl)-2-{4-[1-hydroxy-1-(2-oxa-bicyclo[2.2.2]oct-4-yl)-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416952-67-4 (S)-1-(4-chloro-phenyl)-2-{4-[(R)-1-hydroxy-1-(1-oxo-hexahydro-thiopyran-4-yl)-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416952-68-5 (S)-1-(4-chloro-phenyl)-2-{4-[(S)-1-hydroxy-1-(1-oxo-hexahydro-1-thiopyran-4-yl)-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416952-66-3 (S)-1-(4-chloro-phenyl)-2-{4-[1-hydroxy-1-(1-oxo-hexahydro-1-thiopyran-4-yl)-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416910-09-2 (S)-1-(4-chloro-phenyl)-2-{4-[(R)-1-(1,1-dioxo-hexahydro-1-thiopyran-4-yl)-1-hydroxy-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416910-10-5 (S)-1-(4-chloro-phenyl)-2-{4-[(S)-1-(1,1-dioxo-hexahydro-1-thiopyran-4-yl)-1-hydroxy-ethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1416910-07-0 (S)-1-(4-chloro-phenyl)-2-{4-[1-(1,1-dioxo-hexahydro-1-thiopyran-4-yl)-1-hydroxyethyl]-phenyl}-7-isopropoxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 
• 1313367-13-3 (S)-1-(4-Chloro-phenyl)-7-hydroxy-6-methoxy-1,4-dihydro-2H-isoquinolin-3-one 

Relevant articles and documents

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

(Figure Presented). As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview of the discovery of this new clinical p53:MDM2 inhibitor. The following aspects are addressed: mechanism of action, scientific rationale, binding mode, medicinal chemistry, pharmacokinetic and pharmacodynamic properties, and in vivo pharmacology/toxicology in preclinical species.

Crystalline form of an inhibitor of MDM2/4 and p53 interaction

A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively,